RT Journal Article
SR Electronic
T1 The impact of psychological treatment on catastrophization and pharmacological response in chronic migraine: A single-center experience
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.08.24315876
DO 10.1101/2024.11.08.24315876
A1 Sepe, Federica Nicoletta
A1 Lanni, Claudia
A1 De Michelis, Daniele
A1 Lancia, Giacomo
YR 2024
UL http://medrxiv.org/content/early/2024/11/08/2024.11.08.24315876.abstract
AB Background We aimed to assess the impact of pain catastrophizing, measured using the Italian version of the Pain Catastrophizing Scale (PCS), on the clinical response of patients with chronic migraine to anti-CGRP monoclonal antibodies combined with a multidisciplinary approach, including psychological treatment.Methods 25 Outpatients from SS. Antonio e Biagio e Cesare Arrigo headache clinic randomly assigned to receive Galcanezumab, Erenumab, or Fremanezumab. Their clinical response was evaluated over six months using various measures, including reducing the number of days with migraine per month, and quality of life using Headache Impact Test (HIT 6), MIgraine Disability Assessment Score questionnaire (MIDAS), and Beck’s Inventory Scale (BDI II) scales to assess comorbid depression.Results We established a strong correlation between HIT 6 and PCS, with coefficients of 0.81 and 0.88 at T1 and T2, respectively. Furthermore, we found no significant correlation between PCS and the other scales, such as MIDAS, as with any pharmacological therapies.Conclusion This study aims to clearly define the impact of a multidisciplinary approach including a psychological follow-up on a particular clinical phenotype of chronic migraines and their tendency to catastrophize, but more extended data are needed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding declaration not availableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Azienda Sanitaria SS. Antonio e Biagio e Cesare Arrigo, Headache Clinic, Department of Neurology, located in Alessandra, Italy. Approval was granted in 2021, under protocol reference number ASO.NEURO.21.02. The ethics committee confirmed that the study complies with all relevant ethical standards. All participants provided written informed consent prior to participation in accordance with the ethical standards of the Ethics Committee of the Azienda Sanitaria SS. Antonio e Biagio e Cesare Arrigo.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript